OrthoPediatrics

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OrthoPediatrics achieves record revenue growth and eyes international expansion

OrthoPediatrics delivered strong financial performance in 2022, achieving profitability and record revenue growth despite challenges. With a focus on new product launches, international expansion, and surgeon training, the company is well-positioned for continued growth and profitability.

OrthoPediatrics reports robust Q1 earnings, eyes international growth opportunities

OrthoPediatrics had a strong Q1 2023, with increased revenue guidance for the full year. The company remains cautiously optimistic due to staffing dynamics. Focus on new product development, acquisitions, and addressing digital needs of children's hospitals highlight growth strategies.

OrthoPediatrics achieves record Q2 performance amidst growth challenges

OrthoPediatrics delivered strong Q2 results with record child assistance and revenue growth, driven by trauma, deformity, and international segments.
While facing challenges like atypical growth patterns and delays in product launches, the company is well-positioned to capitalize on opportunities in enabling technologies and international expansion.
The focus on long-term growth drivers and strategic acquisitions underscores OrthoPediatrics' commitment to sustainable growth and innovation in pediatric orthopedics.
Overall, OrthoPediatrics' performance highlights operational efficiency, market demand, and a clear path for future growth and expansion.

OrthoPediatrics achieves record revenue in Q3 2023, eyes continued growth

OrthoPediatrics reported strong financial performance in Q3 2023, with record revenue and EBITDA, positioning the company for future growth. Despite challenges in certain segments, opportunities in new product launches, international expansion, and surgeon training initiatives offer avenues for continued success. The company's positive outlook and robust pipeline indicate a promising trajectory for OrthoPediatrics.

OrthoPediatrics achieves record revenue and EBITDA, eyes international expansion

OrthoPediatrics delivered strong financial performance in 2023, setting revenue and EBITDA records. The company's strategic focus on sustainable growth, profitability, and diversification positions it well for future success.

OrthoPediatrics reports robust Q1 growth, raises full-year revenue guidance

OrthoPediatrics demonstrated strong performance in Q1 2024 with significant growth in patients helped, revenue, and key business segments. While facing challenges such as an EBITDA loss and increased expenses, the company's focus on growth, new product launches, and financial targets positions it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WARSAW, Ind., Aug.  24, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued Diamond sponsorship for the virtual 30th Annual Baltimore Limb Deformity Course (“BLDC”). The highly anticipated industry course will feature a virtual exhibition with live virtual sessions on August 29-30, 2020.

OrthoPediatrics Corp. Maintains its Diamond Sponsorship for Virtual 30th Annual Baltimore Limb Deformity Course (“BLDC”)

WARSAW, Ind., Aug.  10, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Mark Throdahl, Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Dave Bailey, President, are scheduled to participate in the 5th Annual Needham Virtual Med Tech 1x1 Conference. Management will host virtual one-on-one investor meetings on Monday, August 17, 2020.

OrthoPediatrics Corp. to Participate in the 5th Annual Needham Virtual Med Tech 1x1 Conference

OrthoPediatrics Corp. (KIDS) CEO Mark Throdahl on Q2 2020 Results - Earnings Call Transcript

Company’s partnership with Mighty Oak Medical for 3D printed, patient-specific technology continues advancing pediatric scoliosis treatment Company’s partnership with Mighty Oak Medical for 3D printed, patient-specific technology continues advancing pediatric scoliosis treatment

OrthoPediatrics Corp. Achieves 500th Case with FIREFLY® Pedicle Screw Navigation Guides

OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: OrthoPediatrics (KIDS) Q2 Earnings Expected to Decline

Conference Call to Discuss Results on August 6, 2020 at 8:00 a.m. ET Conference Call to Discuss Results on August 6, 2020 at 8:00 a.m. ET

OrthoPediatrics Corp. to Report Second Quarter 2020 Financial Results on August 5, 2020

WARSAW, Ind., June  22, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today the closing of its underwritten public offering of 1,600,000 shares of its common stock at a price to the public of $47.00 per share. Gross proceeds to OrthoPediatrics were approximately $75.2 million, before deducting underwriting discounts and commissions and offering expenses payable by OrthoPediatrics.

OrthoPediatrics Corp. Announces Closing of Offering of Common Stock

WARSAW, Ind., June  18, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today the pricing of its underwritten public offering of 1,600,000 shares of its common stock at a price to the public of $47.00 per share.

OrthoPediatrics Corp. Announces Pricing of Offering of Common Stock

WARSAW, Ind., June  17, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today that it is commencing an underwritten public offering of its common stock. OrthoPediatrics intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

OrthoPediatrics Corp. Announces Proposed Public Offering of Common Stock

ApiFix, the only posterior motion-preserving scoliosis correction technology available in the U.S., provides unique advantages for treating progressive adolescent idiopathic scoliosis ApiFix, the only posterior motion-preserving scoliosis correction technology available in the U.S., provides unique advantages for treating progressive adolescent idiopathic scoliosis

OrthoPediatrics Corp. Commences Initial U.S.

OrthoPediatrics Corp. (KIDS) CEO Mark Throdahl on Q1 2020 Results - Earnings Call Transcript

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -11.11% and -3.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

OrthoPediatrics (KIDS) Reports Q1 Loss, Misses Revenue Estimates

Analysts Estimate OrthoPediatrics (KIDS) to Report a Decline in Earnings: What to Look Out for

OrthoPediatrics Corp. Is Now Wildly Overvalued

WARSAW, Ind., March  31, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to expand the indications for its RESPONSE™ Scoliosis System to include neuromuscular implants.

OrthoPediatrics Corp. Receives FDA 510(k) Clearance and Expanded Neuromuscular Indications for its RESPONSE™ Scoliosis System

WARSAW, Ind., March  30, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today provided a business update on the proactive steps it is taking in response to the global COVID-19 pandemic.

OrthoPediatrics Corp. Provides COVID-19 Business Update

OrthoPediatrics (KIDS) releases the latest cannulated screw system as part of its beta release to address trauma as well as other bone fixation procedures.

OrthoPediatrics Announces Latest Screw System Launch in US

WARSAW, Ind., March  09, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, is pleased to announce the limited U.S. launch of its Large Fragment Cannulated Screw System, which would represent the Company’s 34th surgical system. The innovative system was designed to address trauma procedures, as well as treating children with a condition known as Slipped Capital Femoral Epiphysis (“SCFE”) and includes specific design elements to address the unique needs of the pediatric population.

OrthoPediatrics Corp. Announces U.S.

OrthoPediatrics Corp. (KIDS) CEO Mark Throdahl on Q4 2019 Results - Earnings Call Transcript

WARSAW, Ind., Feb.  26, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, is pleased to announce that it was recently named  one of the Best Places to Work in Indiana by the Indiana Chamber of Commerce and Best Companies Group. OrthoPediatrics’ recognition and inclusion in the fifteenth annual program is the fourth time the Company has been honored with this award.

OrthoPediatrics Corp. Continues to be Honored as One of the Best Place to Work in Indiana

CatchMark Timber Trust

Empire State Realty Trust

Global Water Resources

New York Community Bancorp

Rocky Mountain Chocolate

ONE Group Hospitality

Are you worried about overvalued markets and overpriced tech stocks? These seven small stocks are a great way to diversify your holdings.

7 Small Cap Stocks That Pack a Wallop

WARSAW, Ind., Jan.  06, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it has completed the sale of substantially all of the assets related to the adult product offering of Vilex in Tennessee, Inc. (“Vilex Adult Business”) to Vilex LLC (“Buyer”), an affiliate of Squadron Capital LLC (“Squadron Capital”). In addition, Buyer was granted a license to manufacture and sell products utilizing the external fixation technology developed by Orthex, LLC, an affiliate of OrthoPediatrics, subject to certain restrictions in favor of OrthoPediatrics on sales to certain pediatric accounts. The divestiture was completed on December 31, 2019.

OrthoPediatrics Corp. Announces Divestiture of the Vilex Adult Business

WARSAW, Ind., Dec.  20, 2019  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, is pleased to announce the U.S. launch of QuickPack™, a fully synthetic bone graft substitute featuring a high viscosity, calcium phosphate cement that closely mimics the mineral phase of natural bone.

OrthoPediatrics Corp. Announces U.S. Launch of QuickPack™

WARSAW, Ind., Dec.  17, 2019  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today the closing of its underwritten follow-on public offering of 1,805,500 shares of its common stock at a price to the public of $36.50 per share, which included the exercise in full by the underwriters of their option to purchase additional shares of common stock on the same terms and conditions. 1,755,500 of the shares were offered by OrthoPediatrics and 50,000 shares were offered by certain selling stockholders. Gross proceeds to OrthoPediatrics were approximately $64.1 million, before deducting underwriting discounts and commissions and offering expenses payable by OrthoPediatrics.

OrthoPediatrics Corp. Announces Closing of Common Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WARSAW, Ind., Dec.  11, 2019  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today the pricing of its underwritten public offering of 1,570,000 shares of its common stock at a price to the public of $36.50 per share. 1,520,000 of the shares are being offered by OrthoPediatrics and 50,000 shares are being offered by certain selling stockholders. OrthoPediatrics will not receive any proceeds from the sale of the shares by the selling stockholders.

News for OrthoPediatrics Stock (KIDS)